论文部分内容阅读
本文介绍6组急性心肌梗塞(AMI)患者作溶栓治疗中发生的中风,其中3组用链激酶,3组用组织纤维蛋白溶酶原致活剂(t-PA)作溶栓剂。表1总结用链激酶治疗情况。中风的发生率,治疗组与安慰剂组无差异。颅内出血在治疗组较多。大部分患者的中风不能分型。表2总结用t-PA治疗情况。中风的发生率,治疗组与安慰剂组无差异。颅内出血在治疗组较多。少数患者不能分型。从这些资料亦说明有必要作更仔细的观察来分型,并据此选择不同的溶栓治疗。链激酶组中Ⅰ组于停用链激酶后用肝素,Ⅱ组则完全
This article describes stroke in thrombolytic therapy in 6 AMI patients, 3 with streptokinase and 3 with tissue plasminogen activator (t-PA) as a thrombolytic agent. Table 1 summarizes the treatment with streptokinase. The incidence of stroke was no different between the treatment and placebo groups. Intracranial hemorrhage in the treatment group more. Most patients with stroke can not type. Table 2 summarizes the treatment with t-PA. The incidence of stroke was no different between the treatment and placebo groups. Intracranial hemorrhage in the treatment group more. A small number of patients can not type. From these data also shows the need for more careful observation to type, and thus choose a different thrombolytic therapy. In streptokinase group, heparin was used in group I and streptokinase in group I, while group II was complete